NIA appropriations for Alzheimer’s disease and related dementias (ADRD) has increased to $400 million in FY 2017. And this, along with increases to NIA’s general appropriation, raised the general funding line “substantially,” according to Robin Barr, NIA’s Director of DEA. He adds: “We hope we have unleashed a wave of research on aging and on Alzheimer’s that will help generate the breakthroughs we so urgently need in our rapidly aging society.”
Announcement